Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03363555
Recruitment Status : Active, not recruiting
First Posted : December 6, 2017
Last Update Posted : June 18, 2020
Sponsor:
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:
This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

Condition or disease Intervention/treatment Phase
Extranodal NK/T-cell Lymphoma, Nasal Type Drug: SHR-1210 Phase 2

Detailed Description:
The primary objective of this phase 2 study is to assess objective response rate of SHR-1210 in patients with relapsed or refractory extranodal NK/T cell lymphoma. The secondary objective is to observe time to response,progression free survival rate at 2 years,overall survival rate at 2 years,safety and immunogenicity of SHR-1210 in relapsed or refractory extranodal NK/T cell lymphoma.The relationship of PD-L1 expression in tumor tissue and EBV-DNA copies in blood to SHR-1210 efficacy in these patients would also be explored.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 97 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
Actual Study Start Date : May 29, 2018
Actual Primary Completion Date : June 30, 2019
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: SHR-1210
SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
Drug: SHR-1210
A humanized monoclonal immunoglobulin.




Primary Outcome Measures :
  1. objective response rate [ Time Frame: from first patient first visit to 6 month after last patient first visit ]
    rate of subjects achieved complete response plus partial response in all evaluable subjects



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed extranodal NK/T cell lymphoma;
  2. Relapsed or refrsctory cHL and received L-asparaginase based chemotherapy.
  3. Subjects enrolled have measurable lesion(s) according to Lugano 2014 criteria
  4. Need to provide ≥5 tumor tissue sections for detection.
  5. ECOG performance status of 0 or 1;
  6. Life expectancy ≥ 12 weeks.;
  7. Adequate laboratory parameters during the screening period as evidenced by the following:

    1. Absolute neutrophil count ≥ 1.0× 109/L ;
    2. Platelets ≥ 75 × 109/L;
    3. Hemoglobin ≥ 8.0 g/dL;
    4. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), ALT and AST ≤ 2.5×ULN
    5. Serum Creatinine ≤1.25×ULN or Creatinine clearance≥45 mL/min;
    6. Coagulation function index:INR ≤1.5×ULN,APTT≤1.5×ULN
  8. Women of childbearing potential must be willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy while on treatment and for at least 60 days after receiving the last dose of study treatment. Women of childbearing potential with pregnancy test negative within 7days before entering the group and not in in lactation; Male subjects with WOCBP partner should receive Surgical sterilization orconsent to employ a highly effective method of birth control/contraception to prevent pregnancy while on treatment and for at least 120 days after receiving the last dose of study treatment.
  9. Able to understand and sign an informed consent form (ICF).

Exclusion Criteria:

  1. invasive NK cell leukemia or precursor NK cell tumor
  2. Known central nervous system lymphoma
  3. Haemophilus cell syndrome at diagnosis
  4. Large lung vessels were involved
  5. History and complication

    1. Recieved anti-tumor vaccines or other anti-tumor therapy with immune stimulation within 3 months.
    2. Prior exposure to any PD-1/PD-L1/PD -L 2 or CTLA -4 antibody .
    3. Participating in other clinical studies or less than 4 weeks before the end of a clinical trial;
    4. Active, known or suspected autoimmune disease. Subjects who were in a stable state without systemic immunosuppressive therapy were admitted.
    5. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids > 10mg.
    6. Known and suspicion of interstitial pneumonia
    7. Other active malignancies that required treating.
    8. Received chemotherapy, radiotherapy,immunotherapy, including topical therapy within 4 weeks. Previous anti-tumor therapy related adverse reactions (except trichomadesis) did not recover to CTCAE ≤1.
    9. Prior allo-HSCT.
    10. ASCT within 90 days.
    11. Impact of major surgery or severe trauma had been eliminated for less than 14 days.
    12. Active pulmonary tuberculosis.
    13. Severe acute or chronic infection requiring systemic therapy.
    14. Suffering from heart failure (New York Heart Association standard III or IV) and given appropriate medical treatment.Uncontrolled coronary artery disease and arrhythmia. History of myocardial infarction within 6 months.
  6. laboratory test

    1. known HIV positive or known AIDS.
    2. Untreated active hepatitis; Hepatitis B and hepatitis C infection in common.
  7. Other factors that may lead to the study termination, such as severe disease or abnormal laboratory tests or family or social factors affecting subjects safety or test data and sample collection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03363555


Locations
Layout table for location information
China, Henan
First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Layout table for additonal information
Responsible Party: Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier: NCT03363555    
Other Study ID Numbers: SHR-1210-II-205
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: June 18, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, T-Cell
Lymphoma, Extranodal NK-T-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin